GlassScriptPhysician profile
Joseph C Mueller
NPI 1013170794
$9,042.79
in general payments reported to CMS, 2019-2025
37 companies · $768 in 2025
The $768 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $929 · 2020: $503 · 2021: $447 · 2022: $774 · 2023: $4,879 · 2024: $743 · 2025: $768.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $3,000 · Food and Beverage: $2,434 · Travel and Lodging: $956.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $3,000.00 |
| Food and Beverage | $2,434.46 |
| Travel and Lodging | $956.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $3,956.07 | 2023 | Ion, Da Vinci Surgical System |
| Glaxosmithkline, LLC. | $744.31 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Genzyme Corporation | $417.68 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $347.43 | 2019-2024 | Tagrisso, Fasenra |
| Grifols USA, LLC | $335.15 | 2019-2025 | Prolastin-C Liquid |
| Mallinckrodt Hospital Products INC. | $229.83 | 2022-2024 | Acthar |
| Boehringer Ingelheim Pharmaceuticals, INC. | $214.22 | 2019-2022 | |
| Pfizer INC. | $209.46 | 2023-2025 | |
| Amgen INC. | $208.24 | 2021-2025 | Tezspire |
| Shionogi INC | $205.75 | 2023-2024 | Fetroja |
| Janssen Pharmaceuticals, INC | $200.51 | 2019-2023 | Xarelto |
| Gilead Sciences, INC. | $195.08 | 2022-2024 | Veklury |
| Genentech USA, INC. | $194.41 | 2019-2023 | Xolair |
| Actelion Pharmaceuticals US, INC. | $190.76 | 2019-2025 | Opsumit, Uptravi, Opsynvi |
| Regeneron Healthcare Solutions, INC. | $159.10 | 2019-2024 | Dupixent |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| United Therapeutics Corporation | $137.74 | 2022-2025 | Tyvaso, Tyvaso |
| Mylan Specialty L.P. | $137.22 | 2020-2024 | Yupelri |
| Takeda Pharmaceuticals U.S.A., INC. | $137.10 | 2020-2025 | Aralast, Glassia |
| Viatris Specialty LLC | $119.07 | 2025 | Yupelri |
| Merck Sharp & Dohme LLC | $114.05 | 2019 | |
| Insmed, INC. | $77.47 | 2019-2025 | Arikayce |
| Csl Behring | $75.03 | 2025 | Kcentra |
| Baxter Healthcare | $60.46 | 2023-2025 | Hillrom - Vest System Model 105 Home Care, Hillrom - Life 2000 Ventilation System |
| Axsome Therapeutics, INC. | $52.38 | 2023-2024 | Sunosi |
| Paratek Pharmaceuticals, INC. | $46.45 | 2023 | Nuzyra |
| Novartis Pharmaceuticals Corporation | $38.11 | 2019 | |
| Electromed, INC. | $34.59 | 2021-2022 | |
| Circassia INC. | $32.88 | 2019 | |
| Tempus Ai, INC | $29.42 | 2024 | |
| Sunovion Pharmaceuticals INC. | $26.65 | 2019 | |
| Verona Pharma, INC. | $20.96 | 2025 | Ohtuvayre |
| Tactile Systems Technology INC | $20.42 | 2022 | |
| Lilly USA, LLC | $18.62 | 2025 | Zepbound |
| Shire North American Group INC | $15.80 | 2019 | |
| Idorsia Pharmaceuticals US INC | $14.73 | 2023 | Quviviq |
| Teva Pharmaceuticals USA, INC. | $13.13 | 2022 | |
| Philips North America LLC | $12.51 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Mueller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.